Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025
Peroral plication of the esophagus as a treatment option for end-stage achalasia with sump formation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alexander Ryan G, Wong Kee Song Louis M, Nehra Avinash K, Alexander Jeffrey A, Codipilly Don C, Blackmon Shanda H, Ravi Karthik
Аннотация
INTRODUCTION: Peroral plication of the esophagus (POPE) can reduce sump size and improve symptoms in end-stage achalasia. However, its long-term efficacy and safety are unknown.
METHODS: Patients with end-stage achalasia who underwent POPE at our institution (2016-2024) were identified. Data were abstracted for patient demographics, procedural details, and clinical and radiographic outcomes.
RESULTS: Twelve patients underwent POPE. The technical success rate was 100%, with mean procedural time of 57 minutes and without adverse events. Symptomatic improvement occurred in 75% of patients (mean follow-up of 15 months), while 86% had radiographic improvement in sump size. Repeat POPE in 6 (50%) patients a mean of 2.6 years after index POPE and a third POPE in four (33%) patients a mean of 3.1 years later was performed, with similar technical success rates and outcomes to the index POPE.
CONCLUSIONS: POPE is a safe and repeatable long-term therapeutic option in end-stage achalasia.
METHODS: Patients with end-stage achalasia who underwent POPE at our institution (2016-2024) were identified. Data were abstracted for patient demographics, procedural details, and clinical and radiographic outcomes.
RESULTS: Twelve patients underwent POPE. The technical success rate was 100%, with mean procedural time of 57 minutes and without adverse events. Symptomatic improvement occurred in 75% of patients (mean follow-up of 15 months), while 86% had radiographic improvement in sump size. Repeat POPE in 6 (50%) patients a mean of 2.6 years after index POPE and a third POPE in four (33%) patients a mean of 3.1 years later was performed, with similar technical success rates and outcomes to the index POPE.
CONCLUSIONS: POPE is a safe and repeatable long-term therapeutic option in end-stage achalasia.